Zoledronic acid improves bone histomorphometry in a murine model of Rett syndrome

Rett syndrome (RTT) is a neurodevelopmental disorder predominately affecting young females, caused by deficiency of the global transcriptional protein methyl CpG binding protein 2 (MeCP2). Osteoblasts express MeCP2 and girls with RTT experience early onset osteoporosis, decreased bone mass and an increased fracture risk. There is no defined treatment for osteoporosis associated with RTT. The present study evaluated the effects of zoledronic acid (ZA), a third generation nitrogen-containing bisphosphonate with primarily anti-osteoclastic activity, in a mouse model of MeCP2 deficiency.

Source: Bone - March 17, 2017 Category: Orthopaedics Authors: Jay R. Shapiro, Adele L. Boskey, Stephen B. Doty, Lyudmila Lukashova, Mary E. Blue Tags: Full Length Article Source Type: research